Description
Ibrucent (Imbruvica) Ibrutinib 140mg Online
Ibrucent (Imbruvica) Ibrutinib is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It is used to treat mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, Waldenstrom macroglobulinemia, and chronic graft-versus-host disease. Ibrucent is also used to treat cancers such as leukemia, breast cancer, melanoma, lung cancer, and renal cancer. They are also used in the treatment of rheumatoid arthritis and to prevent organ transplant rejection. They work by stopping cancer cell growth and preventing the spread of the cells.
Ibrutinib is a potent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine residue (Cys-481) in the BTK active site, leading to sustained inhibition of BTK enzymatic activity. BTK, a member of the Tec kinase family, is an important signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. The BCR pathway is implicated in the pathogenesis of several B-cell malignancies, including MCL, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and CLL. BTK’s pivotal role in signaling through the B-cell surface receptors results in the activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Preclinical studies have shown that ibrutinib effectively inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.
